Royalty Pharma: Massive Opportunity Ahead
Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...
BioSpace9d
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
CNN1y
Royalty Pharma Plc Class A
Royalty Pharma Plc provides drug development services ... Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta ...
BioSpace14d
Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
Zacks.com on MSN14d
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
In its upcoming report, Royalty Pharma (RPRX) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting an increase of 20.3% compared to the same period last year.